Name:
Jeffrey A Scholten
Country:
USA
City:
Chesterfield
State/Province:
MO
ACS Member:
Member
Local Section:
L523,St. Louis
International Chapter:
Technical Division Membership:
Technical Division Membership Emeritus:
Subdivision Member:
ACS Activities:
Scholten, J. A.; O'Brien, P.; Nahra, J.; Morris, M.; Roark, W. H.; Hanau, C. E.; Ruminski, P. G.; Fletcher, T. R.; Hamper, B. C.; Shieh, H. S.; Collins, B.; McDonald, J.; Rogers, M. D.; Carroll, J. N.; Johnson, A.; Munie, G. E.; Man, C. F.; Settle, S.; Nemirovskiy, O.; Vickery, L. E.; Agawal, A.; Sunyer, T.; Schnute, M. E. Discovery of Highly Selective Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis. 237th American Chemical Society National Meeting & Exposition. Salt Lake City, UT. March 22-26, 2009.
Company/Institution Name:
Career Stage:
Professional
Research and Special Interests:
Over 12 year in the pharmaceutical industry as a Research Scientist with expertise in medicinal chemistry recognized for leadership, problem solving, team building, analysis of large data sets, and synthetic expertise. Successfully leveraged skills to achieve lead development candidates, new chemical entities, development compounds and clinical candidates. Select achievements include: Phase II Nitrous Oxide Synthase Inhibitor, Synthetic step reduction of a steriod replacement from 18 to 8 steps which enable commericial viability, and 2007 ISO 14001 certification as chairperson of the Pfizer Discovery Medicinal Chemistry Safety Committee.
Area of Expertise:
Pharmaceutical experience, multi-step synthesis on small and large scale, technology transfer, library design, analyical expertise which includes FT NMR, FT IR, LC/MS, GC/MS, optical rotation, CO adsorption, automated chromatography normal and reverse phase, microwave reactions
Years of Expertise:
11-15